The menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (Pts) with KMT2A-rearranged or NPM1 mutant AML: Updated results of a phase (Ph) 1 study Meeting Abstract
| Authors: | Issa, G. C.; Aldoss, I.; DiPersio, J. F.; Cuglievan, B.; Stone, R. M.; Arellano, M. L.; Thirman, M. J.; Patel, M. R.; Dickens, D.; Shenoy, S.; Shukla, N.; Rosen, G.; Bagley, R. G.; Meyers, M. L.; Madigan, K.; Ordentlich, P.; Gu, Y.; Smith, S.; McGeehan, G. M.; Stein, E. |
| Abstract Title: | The menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (Pts) with KMT2A-rearranged or NPM1 mutant AML: Updated results of a phase (Ph) 1 study |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 150 |
| End Page: | 152 |
| Language: | English |
| ACCESSION: | WOS:000893223200064 |
| DOI: | 10.1182/blood-2022-164849 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work